{"id":"placebo-matching-nitrofurantoin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo matching nitrofurantoin is not an active pharmaceutical agent but rather an inert formulation designed to be indistinguishable from nitrofurantoin in phase 3 clinical trials. It serves as a control arm to assess the true efficacy of nitrofurantoin by comparing outcomes between patients receiving active drug versus placebo under blinded conditions.","oneSentence":"This is a placebo control formulation matching the appearance and characteristics of nitrofurantoin, used in clinical trials to provide a blinded comparator.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:03.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials of nitrofurantoin (likely urinary tract infection or related indication)"}]},"trialDetails":[{"nctId":"NCT05138822","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-05-18","conditions":"Uncomplicated Urinary Tract Infections, Urinary Tract Infections","enrollment":140},{"nctId":"NCT04187144","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-04-23","conditions":"Urinary Tract Infections","enrollment":1606},{"nctId":"NCT04020341","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-17","conditions":"Urinary Tract Infections","enrollment":1531},{"nctId":"NCT03287089","phase":"PHASE4","title":"Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-09-29","conditions":"Catheter-Associated Urinary Tract Infection","enrollment":164},{"nctId":"NCT02727322","phase":"PHASE4","title":"Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery","status":"COMPLETED","sponsor":"Halina M Zyczynski, MD","startDate":"2016-08","conditions":"Pelvic Organ Prolapse","enrollment":154},{"nctId":"NCT00752375","phase":"PHASE3","title":"Antibiotic Prophylaxis in Children With Pyelonephritis","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2009-02","conditions":"Pyelonephritis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching nitrofurantoin","genericName":"Placebo matching nitrofurantoin","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation matching the appearance and characteristics of nitrofurantoin, used in clinical trials to provide a blinded comparator. Used for Control arm in phase 3 clinical trials of nitrofurantoin (likely urinary tract infection or related indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}